Interpace Biosciences, Inc.

Total Valuation

Interpace Biosciences, Inc. carries a market capitalization of 48.48M, placing it among publicly traded companies globally. Its enterprise value stands at 15.47M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Interpace Biosciences, Inc. currently has 27.70M shares outstanding.

Valuation Ratios

Interpace Biosciences, Inc. trades at a trailing price-to-earnings ratio of 0.72. The price-to-sales ratio is 0.47, and the price-to-book ratio stands at -0.08.

Enterprise Valuation

On an enterprise value basis, Interpace Biosciences, Inc. trades at an EV/EBITDA multiple of 3.66 and an EV/FCF ratio of 2.55. The EV/Sales ratio of 0.43 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 4.58 provides insight into valuation relative to core operating earnings.

Financial Position

Interpace Biosciences, Inc. maintains a current ratio of 2.51, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 4.68, indicating elevated leverage, while an interest coverage ratio of 46.52 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Interpace Biosciences, Inc. has paid -20.93M in income taxes, reflecting an effective tax rate of 26.65.

Stock Price Statistics

Interpace Biosciences, Inc.'s stock has gained approximately 98.86364% over the past 52 weeks. The 50-day moving average sits at 1.93, while the 200-day moving average is 1.40.

Income Statement

Over the trailing twelve months, Interpace Biosciences, Inc. generated 36.24M in revenue and converted that into 23.65M in net income, yielding earnings per share of 1.10. EBITDA reached 4.23M, while operating income came in at 3.38M.

Balance Sheet

Interpace Biosciences, Inc. holds 2.65M in cash and equivalents against 1.08M in total debt, resulting in a net debt position of -2.65M. Total book value stands at -209.44M, with working capital of 6.00M providing operational flexibility.

Cash Flow

Interpace Biosciences, Inc. produced 4.88M in operating cash flow over the past twelve months. After subtracting -497,000.00 in capital expenditures, free cash flow totaled 4.38M - equivalent to 0.49 per share.

Margins

Interpace Biosciences, Inc. operates with a gross margin of 62.53, reflecting its pricing power and cost economics. The operating margin of 9.32 and net profit margin of 65.25 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Interpace Biosciences, Inc.'s most recent stock split took place on January 15, 2020 with a 10:1 split ratio.

Scores

Interpace Biosciences, Inc. posts an Altman Z-Score of -6.18, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.